Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 4/20 | 0.34 |
| ▸ | HTR2A | P28223 | 4/20 | 0.34 |
| ▸ | DRD3 | P35462 | 4/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | CD38 | P28907 | 1/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | TTK | P33981 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 4/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4929908 | 0.87 | PDE4B (0.42) | PDE4BDRD2HTR2ADRD3JAK3 | |
| Trifluoroacetic Acid SCHEMBL4924249 | 0.86 | PDE4B (0.48) | PDE4BCNR2CYP1A2CYP2C9 | |
| Trifluoroacetic Acid SCHEMBL4927212 | 0.83 | PDE4B (0.46) | PDE4B | |
| Trifluoroacetic Acid SCHEMBL4926823 | 0.83 | PDE4B (0.46) | PDE4BDRD2HTR2ADRD3PTK2 | |
| SCHEMBL4923595 | 0.81 | PDE4B (0.53) | PDE4BJAK3KCNH2CNR2CYP2C9 | |
| Trifluoroacetic Acid SCHEMBL4920764 | 0.81 | PDE4B (0.49) | PDE4BKCNH2MAP4K1CYP2C9 | |
| Trifluoroacetic Acid SCHEMBL4920920 | 0.81 | PDE4B (0.45) | PDE4BKCNH2MAP4K1 | |
| Trifluoroacetic Acid SCHEMBL4921100 | 0.80 | PDE4B (0.53) | PDE4BKCNH2CYP2C9 | |
| Trifluoroacetic Acid SCHEMBL4924460 | 0.79 | PDE4B (0.44) | PDE4B | |
| Trifluoroacetic Acid SCHEMBL4930184 | 0.78 | PDE4B (0.47) | PDE4BCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146563-A1 | 1,7-Naphthyridines as Pde4 Inhibitors | GLAXO GROUP LIMITED | 2008-06-19 | — | — | US | claimed |
| US-20080146563-A1 | 1,7-Naphthyridines as Pde4 Inhibitors | GLAXO GROUP LIMITED | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146563-A1 | 1,7-Naphthyridines as Pde4 Inhibitors | PDE4A, PDE3B, PDE4B | PDE4B 3/4885DRD2 345/4885HTR2A 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.